News
Sofinnova Partners and Apollo form strategic partnership in life sciences
NEW YORK & PARIS (May 16, 2022) - Apollo (NYSE: APO) and Sofinnova…
Shionogi Co., Ltd. and F2G Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia
Shionogi to conduct clinical trials, subsequent registration,…
Destiny Pharma – World leading C. difficile scientists to present landmark data on the ability of NTCD-M3 to colonise the gut after antibiotic administration
Brighton, United Kingdom – 12 May 2022 – Destiny Pharma…
Rejuvenate Biomed appoints life sciences leader Dr. Ajit Shetty as Chair of the Board of Directors to help guide international ambitions
Diepenbeek, Belgium, 12 May 2022 – Rejuvenate Biomed NV (“Rejuvenate”),…
ImaginAb announces a new supply agreement with Invicro to offer clinical doses of CD8 investigational ImmunoPET imaging agent for Immuno-Oncology preclinical and clinical studies
Inglewood, California, May 12th, 2022 - ImaginAb Inc., a market-leading…
Novo Holdings backs animal health company Invetx
Novo Holdings today announces it has participated in a $60.5…
vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury
Ronopterin significantly reduces glutamate levels measured…
Novo Nordisk Foundation – Researchers mobilise to combat antimicrobial resistance
Antibiotics are used to treat or prevent some types of bacterial…
ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its Investigational CD8 ImmunoPET Agent
Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market…
AMSilk appoints Klaus Kjedal as Chief Production Officer and Managing Director
Munich, Germany, 04 May 2022 – AMSilk GmbH (“AMSilk”),…
Gadeta to Attend Upcoming Business and Investor Conferences
Utrecht, Netherlands and Boston, Mass., 4th May 2022: Gadeta…
Asceneuron Awarded Second Grant from The Michael J. Fox Foundation for Accelerated Research into Novel Parkinson’s Disease Therapies
Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022…
Neuraxpharm pursues growth strategy for business in Switzerland
The leading European central nervous system specialty company…
Destiny Pharma appoints Dr Yuri Martina as CMO
Destiny Pharma strengthens Executive Management Team with the appointment of Dr Yuri…
Engimmune Therapeutics raises CHF 15.5 million in seed financing to develop novel T-cell receptor therapeutics
Financing co-led by Pureos Bioventures and Novo Holdings with…
Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer
Brings in-depth R&D expertise in oncology, including ADCs,…
STORM Therapeutics Awarded Innovate UK Grant to Discover and Develop a Novel Coronavirus Therapy Targeting an RNA-Modifying Enzyme
03 May 2022, Cambridge, UK: STORM Therapeutics, the biotechnology…
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
Phase 3 ENHANCE-2 trial on target to report top-line COPD data…
ISA Pharmaceuticals to Present at Business Conferences in May 2022
Oegstgeest, 27 April 2022 – ISA is pleased to announce that…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
